Description
Global Markets Direct ' s latest Pharmaceutical and Healthcare disease pipeline guide High-Grade Glioma – Pipeline Review, H2 2016, provides an overview of the High-Grade Glioma( Oncology) pipeline landscape.
Highly grade gliomas( HGG) are tumors of the central nervous system( CNS) that arising from transformed cells of the brain and spinal cord. Symptoms include developmental delay, headaches, backaches, nausea and vomiting, dizziness, gait disturbances, impaired vision, lack of concentration, drowsiness, sleep disturbances, Dysregulated appetite, paralyses and seizures. Treatment includes Chemotherapy and radiation therapy.
Request a sample of this report @ http:// orbisresearch. com / contacts / request-sample / 171244.
Report Highlights Global Markets Direct ' s Pharmaceutical and Healthcare latest pipeline guide High-Grade Glioma – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for High-Grade Glioma( Oncology), complete with analysis by stage of development, drug target, mechanism of action( MoA), route of administration( RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
Purchase a copy of this report @ http:// orbisresearch. com / contact / purchase / 171244. For more information contact sales @ orbisresearch. com
The High-Grade Glioma( Oncology) pipeline guide also reviews of key players involved in therapeutic development for High-Grade Glioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies / Universities / Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 10, 10, 3 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 2, 1 and 2 molecules, respectively.
High-Grade Glioma( Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’ s proprietary databases, company / university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company / university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Browse Complete Report @ http:// orbisresearch. com / reports / index / high-grade-glioma-pipelinereview-h2-2016.
Some points from TOC: www. orbisresearch. com; + 1( 214) 884-6817; + 9120-64101019